HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenberg, J. M. Search for Related Content PubMed PubMed Citation Articles by Rosenberg, J. M.

JACK M. ROSENBERG, PHARM.D., PH.D., is Director, International Drug Information Center, and Professor of Pharmacology and Pharmacy, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 75 DeKalb Avenue, Brooklyn, NY 11201 (j666666{at}attglobal.net).

Purpose. Medicare Part D prescription drug benefits are reviewed. Potential implications for patients with psychotic disorders in relation to Medicare Part D are discussed. Summary. The newly created Medicare Part D provides prescription drug benefits to many individuals formerly without prescription benefits and, possibly, lower-cost benefits to those who previously relied on other benefits. Participating prescription plans use a variety of pharmacy management tools to minimize costs while providing benefit plans that meet Part D requirements for composition and coverage. Patients then have the challenge of choosing a prescription drug plan that will best satisfy their prescriptions needs. Conclusion. The rollout of Part D has not been without problems, and although more Medicare participants are receiving prescription drug benefits at a greater savings, there are concerns that Part D may not provide adequate coverage for all patients or for patients requiring certain types of medications, especially some psychotropic medications. Pharmacists have voiced concerns about the Medicare Part D drug plan in regard to both the degree of coverage it provides to enrollees and the difficulty in administering the benefit. Index terms: Costs; Economics; Health-benefit programs; Laws; Pharmacists; Prescriptions; Psychotherapeutic agents; Psychotic disorders

 

This article has been cited by other articles:

				V. U. Oji, I. Emanaha, and C. Oji Exploring Medication Problems and Strategies for Future Medication Therapy Management in an Outpatient Psychiatric Center Journal of Pharmacy Practice, October 1, 2006; 19(5): 313 - 319. [Abstract] [PDF]